Inclusion Criteria:

- Documented CLL/SLL

- 17p deletion by FISH in 20% or more nuclei on peripheral blood, bone marrow or lymph
node

- Normal organ function

Exclusion Criteria:

- Pregnant or breast feeding

- Current active hepatic or biliary disease

- Chronic or current infectious disease requiring systemic antibiotics, antifungal, or
antiviral treatment such as, but not limited to, chronic renal infection,
tuberculosis and active Hepatitis C

- History of significant cerebrovascular disease in the past 6 months or ongoing event
with active symptoms or sequelae

- Other past or current malignancy. Participants who have been free of malignancy for
at least 2 years, or who have a history of completely resected non-melanoma skin
cancer or successfully treated in situ carcinoma are eligible.

- Known HIV positive

- Clinically significant cardiac disease including unstable angina, acute myocardial
infarction within 6 months prior to study entry, congestive heart failure, and
arrhythmia unless controlled by therapy, with the exception of extra systoles or
minor conduction abnormalities.

- Significant concurrent uncontrolled medical conditions including, but not limited to,
renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or
psychiatric disease which in the opinion of the investigator may represent a risk for
the subject.

- Positive serology for Hepatitis B or C

- History of allergic reactions attributed to ofatumumab.